LPTX RSI Chart
Last 7 days
-4.7%
Last 30 days
-11.7%
Last 90 days
-15.3%
Trailing 12 Months
314.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 2.3M | 2.0M | 1.9M | 1.1M |
2022 | 1.4M | 1.6M | 1.8M | 2.1M |
2021 | 1.8M | 1.8M | 2.9M | 1.2M |
2020 | 2.2M | 2.5M | 2.8M | 1.8M |
2019 | 1.0M | 1.3M | 1.6M | 1.9M |
2018 | 1.5M | 1.2M | 995.8K | 756.0K |
2017 | 2.8M | 2.4M | 2.1M | 1.7M |
2016 | 0 | 0 | 0 | 3.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 26, 2024 | mirabelli christopher | acquired | - | - | 5,000 | chairman of the board |
Jan 26, 2024 | lawlor augustine | acquired | - | - | 5,000 | chief operating officer |
Jan 26, 2024 | onsi douglas e | acquired | - | - | 7,500 | ceo,cfo,pres.,gc,treas.,&sec. |
Jan 26, 2024 | sirard cynthia | acquired | - | - | 5,000 | chief medical officer |
Jan 26, 2024 | o'mahony john mark | acquired | - | - | 5,000 | chief manufacturing officer |
Mar 17, 2023 | onsi douglas e | acquired | - | - | 660,606 | ceo,cfo,pres.,gc,treas.,&sec. |
Sep 24, 2021 | beigene, ltd. | bought | 7,249,830 | 2.85 | 2,543,800 | - |
Dec 28, 2020 | healthcare ventures viii, l.p. | sold | - | - | -2,618,410 | - |
Jun 22, 2020 | perceptive advisors llc | bought | 3,500,000 | 2.00 | 1,750,000 | - |
Feb 05, 2019 | mirabelli christopher | bought | 999,999 | 1.75 | 571,428 | ceo, president, chairman |
Which funds bought or sold LPTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | new | - | 40,320 | 40,320 | -% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | -1,740,680 | 3,117,990 | 0.04% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | sold off | -100 | -186,404 | - | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | reduced | -49.09 | -2,631,600 | 1,276,800 | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | reduced | -25.19 | -309,460 | 285,716 | 0.02% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | -2,000 | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 48,627 | 48,627 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 4.18 | -937,886 | 1,892,110 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -93,871 | 168,147 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -12.98 | -2,298 | 2,908 | -% |
Unveiling Leap Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Leap Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Leap Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -38.5% | 246,000 | 400,000 | 554,000 | 298,000 | 272,000 | 775,000 | 652,000 | 587,000 | 814,333 | 1,041,667 | 1,269,000 | 375,000 | 375,000 | 839,500 | 228,000 | 375,000 | 375,000 | 1,794,000 | 927,500 | 61,000 | 75,000 |
Operating Expenses | 0.0% | 14,825,000 | 14,820,000 | 14,833,000 | 14,662,000 | 42,726,000 | 13,943,000 | 15,288,000 | 16,900,000 | 10,632,000 | 10,863,000 | 12,515,000 | 10,001,000 | 9,547,000 | 7,529,000 | 7,883,000 | 7,871,000 | 6,756,000 | 8,272,000 | 7,923,000 | 8,461,000 | 8,795,000 |
S&GA Expenses | -100.0% | - | 3,135,000 | 3,330,000 | 3,558,000 | 3,784,000 | 2,909,000 | 3,186,000 | 2,855,000 | 2,848,000 | 2,793,000 | 2,438,000 | 2,795,000 | 2,740,000 | 2,428,000 | 2,514,000 | 2,521,000 | 2,153,000 | 2,604,000 | 2,151,000 | 2,325,000 | 2,005,000 |
R&D Expenses | -3.3% | 11,299,000 | 11,685,000 | 11,503,000 | 11,104,000 | 38,942,000 | 11,034,000 | 12,102,000 | 14,045,000 | 7,784,000 | 8,070,000 | 10,077,000 | 7,206,000 | 6,807,000 | 5,101,000 | 5,369,000 | 5,350,000 | 4,603,000 | 5,668,000 | 5,772,000 | 6,136,000 | 6,790,000 |
EBITDA Margin | 0% | -73.93 | -73.93 | -28.64 | -27.23 | -23.79 | -26.51 | -21.98 | -24.74 | -28.30 | -33.07 | -12.75 | -17.80 | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | 5,000 | 11,000 | 17,000 | 21,000 | 2,000 | 9,000 | 16,000 | 14,000 | -3,000 | 17,000 | 13,000 | 12,000 | 2,000 | 5,000 | 9,000 | 7,000 |
Earnings Before Taxes | - | - | - | - | - | - | - | - | - | - | -10,812,000 | -11,139,000 | -9,526,000 | -9,134,000 | -6,712,000 | -7,057,000 | -6,516,000 | -7,231,000 | -7,999,000 | -7,935,000 | -8,366,000 | -8,603,000 |
EBT Margin | 0% | -73.95 | -73.95 | -28.67 | -27.27 | -23.82 | -26.55 | -22.01 | -24.79 | -28.35 | -33.12 | -12.77 | -17.84 | - | - | - | - | - | - | - | - | - |
Net Income | -10.9% | -13,820,000 | -12,465,000 | -13,696,000 | -13,390,000 | -41,863,000 | -12,102,000 | -15,094,000 | -17,024,000 | -10,376,000 | -10,788,000 | -11,139,000 | -9,526,000 | -9,134,000 | -6,710,000 | -7,057,000 | -6,516,000 | -7,231,000 | -7,996,000 | -7,935,000 | -8,366,000 | -8,603,000 |
Net Income Margin | 34.4% | -48.48 | -73.95 | -42.68 | -41.29 | -37.66 | -26.62 | -28.88 | -30.10 | -29.21 | -33.11 | -12.77 | -17.84 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -49.5% | -15,516,000 | -10,380,000 | -10,488,000 | -10,185,000 | -12,700,000 | -13,014,000 | -12,253,000 | -12,259,000 | -11,518,000 | -10,716,000 | -8,102,000 | -7,752,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -20.4% | 58.00 | 73.00 | 83.00 | 96.00 | 107 | 70.00 | 82.00 | 94.00 | 106 | 118 | 128 | 38.00 | 46.00 | 54.00 | 61.00 | 68.00 | 29.00 | 7.00 | 14.00 | 20.00 | 26.00 |
Current Assets | -21.5% | 56.00 | 72.00 | 82.00 | 94.00 | 105 | 68.00 | 80.00 | 92.00 | 105 | 117 | 125 | 36.00 | 44.00 | 52.00 | 58.00 | 65.00 | 26.00 | 4.00 | 11.00 | 17.00 | 23.00 |
Cash Equivalents | -22.3% | 55.00 | 71.00 | 81.00 | 91.00 | 102 | 66.00 | 78.00 | 91.00 | 103 | 115 | 125 | 36.00 | 43.00 | 52.00 | 52.00 | 65.00 | 25.00 | 4.00 | 10.00 | 16.00 | 22.00 |
Net PPE | -100.0% | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -16.5% | 11.00 | 13.00 | 11.00 | 12.00 | 11.00 | 11.00 | 12.00 | 11.00 | 7.00 | 10.00 | 11.00 | 8.00 | 7.00 | 8.00 | 7.00 | 8.00 | 11.00 | 9.00 | 9.00 | 9.00 | 9.00 |
Current Liabilities | -17.7% | 10.00 | 13.00 | 11.00 | 12.00 | 10.00 | 11.00 | 12.00 | 10.00 | 7.00 | 10.00 | 11.00 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 9.00 | 8.00 | 8.00 | 8.00 | 8.00 |
Shareholder's Equity | -21.2% | 47.00 | 60.00 | 72.00 | 84.00 | 28.00 | 59.00 | 70.00 | 83.00 | 99.00 | 108 | 117 | 30.00 | 38.00 | 47.00 | 53.00 | 60.00 | 18.00 | - | 6.00 | 11.00 | 17.00 |
Retained Earnings | -3.5% | -413 | -399 | -387 | -373 | -360 | -318 | -306 | -290 | -273 | -263 | -252 | -241 | -232 | -222 | -216 | -209 | -202 | -195 | -187 | -179 | -170 |
Additional Paid-In Capital | 0.3% | 461 | 460 | 458 | 457 | 388 | 377 | 375 | 374 | 373 | 372 | 370 | 272 | 271 | 270 | 269 | 269 | 220 | 193 | 192 | 190 | 188 |
Shares Outstanding | 0.1% | 26.00 | 26.00 | 26.00 | 26.00 | 12.00 | 10.00 | 11.00 | 11.00 | 11.00 | 6.00 | 8.00 | 8.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 78.00 | - | - | - | 94.00 | - | - | - | 86,766,207 | - | - | - | 109 | - | - | - | 28.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -49.5% | -15,516 | -10,380 | -10,488 | -10,185 | -12,700 | -13,014 | -12,253 | -12,259 | -11,518 | -10,716 | -8,102 | -7,752 | -8,587 | -5,988 | -6,592 | -9,451 | -3,926 | -5,894 | -6,957 | -7,183 | -6,868 |
Share Based Compensation | -0.4% | 1,248 | 1,253 | 1,300 | 1,265 | 1,310 | 1,457 | 1,253 | 1,266 | 1,204 | 938 | 1,003 | 912 | 833 | 715 | 670 | 617 | 570 | 936 | 950 | 899 | 947 |
Cashflow From Investing | - | - | - | - | -348 | 49,317 | - | - | - | - | - | - | - | - | - | - | - | - | 15.00 | - | - | - |
Cashflow From Financing | - | 29.00 | - | -1.00 | - | -29.00 | - | - | - | -210 | 755 | 97,262 | 4.00 | 14.00 | - | -385 | 48,777 | 25,605 | -19.00 | 1,254 | 1,260 | 12,322 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 11,299 | $ 38,942 |
General and administrative | 3,526 | 3,784 |
Total operating expenses | 14,825 | 42,726 |
Loss from operations | (14,825) | (42,726) |
Interest income | 775 | 848 |
Australian research and development incentives | 246 | 272 |
Foreign currency loss | (16) | (307) |
Change in fair value of Series X preferred stock warrant liability | 50 | |
Net loss | $ (13,820) | $ (41,863) |
Net loss per share | ||
Basic (in dollars per share) | $ (0.51) | $ (3.24) |
Diluted (in dollars per share) | $ (0.51) | $ (3.24) |
Weighted average common shares outstanding | ||
Basic (in shares) | 27,014,100 | 12,934,427 |
Diluted (in shares) | 27,014,100 | 12,934,427 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 54,921 | $ 70,643 |
Research and development incentive receivable | 738 | 771 |
Prepaid expenses and other current assets | 526 | 183 |
Total current assets | 56,185 | 71,597 |
Property and equipment, net | 5 | |
Right of use assets, net | 577 | 257 |
Research and development incentive receivable, net of current portion | 245 | |
Deferred costs | 39 | |
Deposits | 917 | 966 |
Total assets | 57,963 | 72,825 |
Current liabilities: | ||
Accounts payable | 5,951 | 6,465 |
Accrued expenses | 4,056 | 5,957 |
Lease liability - current portion | 430 | 262 |
Total current liabilities | 10,437 | 12,684 |
Non current liabilities: | ||
Lease liability, net of current portion | 154 | |
Total liabilities | 10,591 | 12,684 |
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding | ||
Common stock, $0.001 par value; 240,000,000 shares authorized; 25,603,471 and 25,565,414 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 26 | 26 |
Additional paid-in capital | 460,868 | 459,591 |
Accumulated other comprehensive income (loss) | (120) | 106 |
Accumulated deficit | (413,402) | (399,582) |
Total stockholders' equity | 47,372 | 60,141 |
Total liabilities and stockholders' equity | $ 57,963 | $ 72,825 |